Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 7,410,000 shares, an increase of 9.3% from the September 30th total of 6,780,000 shares. Currently, 10.4% of the shares of the stock are sold short. […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) major shareholder Bain Capital Investors Llc purchased 5,480,052 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was purchased at an average price of $22.81 per share, for a total transaction of $124,999,986.12. Following the acquisition, the insider now owns […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 6,020,000 shares, an increase of 10.7% from the August 31st total of 5,440,000 shares. Based on an average daily volume of 659,700 shares, the short-interest […]
Piper Sandler initiated coverage on shares of Cerevel Therapeutics (NASDAQ:CERE – Free Report) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $33.00 price objective on the biotechnology company’s stock. CERE has been the subject of a number of other reports. Bank of America […]